Oral Ivarmacitinib for Stable Vitiligo: Preliminary Observations from a Three-Patient Case Series

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Vitiligo is an autoimmune disorder causing melanocyte loss.
• Stable vitiligo often shows limited response to conventional therapies.
• The JAK-STAT pathway is implicated in vitiligo's inflammatory processes.

Purpose of the Study:

• To investigate the potential of ivarmacitinib, a JAK1 inhibitor, in treating stable vitiligo.
• To observe the 12-week clinical outcomes of patients with stable vitiligo receiving oral ivarmacitinib.

Main Methods:

• A case series of three patients (12-50 years old) with stable vitiligo.
• Treatment involved oral ivarmacitinib at varying doses (4 mg daily or every other day).
• Clinical observations and lesion evaluations were conducted over 12 weeks.

Main Results:

• All three patients demonstrated improvement in skin lesions.
• 73.58% of lesions showed complete or near-complete repigmentation.
• Repigmentation varied by anatomical site, with faster responses on the face and trunk.

Conclusions:

• Preliminary 12-week data suggest oral ivarmacitinib may promote repigmentation in stable vitiligo.
• Findings are limited by small sample size and lack of control group.
• Further prospective studies are needed to establish efficacy and safety.